[Skip to Navigation]
Sign In
Comment & Response
July 13, 2017

Overestimating the Benefit of Cancer Drugs

Author Affiliations
  • 1Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland
JAMA Oncol. 2017;3(12):1737-1738. doi:10.1001/jamaoncol.2017.0107

To the Editor Salas-Vega et al1 report that new cancer drugs approved between 2003 and 2013 improved overall survival (OS) by a mean of 3.43 months. This magnitude is greater than the median of 2.1 months reported by Fojo et al2 for drugs approved between 2002 and 2014 for solid tumors. Several observations may explain the difference.

Add or change institution